Valcrest Pharmaceuticals

Valcrest Pharmaceuticals, based in Pelham, New York, is dedicated to developing and commercializing novel treatments for ultra-rare orphan diseases. With a current focus on Mastocytosis, the company leverages its expertise in FDA regulatory requirements, clinical development, manufacturing, API sourcing, formulation development, and product commercialization.

Valcrest Pharmaceuticals has made significant strides in addressing the unmet needs of patients with ultra-rare conditions. The founding team brings deep experience in the rare disease market, ensuring a robust approach to drug development and market introduction.